News from immunovia ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 26, 2019, 11:44 ET Immunovia - Report from AGM

The Annual General Meeting (AGM) of Immunovia AB (publ), corporate identity number 556730-4299 was held at Gamla Gästmatsalen in Medicon Village,...


Apr 24, 2019, 10:57 ET CORRECTION: Immunovia Interim Report, January-March 2019

(The previous release was sent at 10.23 CET and has been updated with accurate dates in the key indicators of the Swedish version. The correct dates...


Apr 24, 2019, 04:33 ET Immunovia Interim Report, January-March 2019

During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key...


Apr 10, 2019, 02:24 ET Corrected: Immunovia and University College of London Sign Agreement to Expand Validation Studies of IMMray™ PanCan-d for Early Signs and Symptoms

Immunovia today announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL)...


Apr 08, 2019, 09:33 ET Immunovia and University College of London Sign Agreement to Extend Validation Studies of IMMray™ PanCan-d for Early Signs and Symptoms

Immunovia today announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL)...


Mar 04, 2019, 04:08 ET Immunovia Publishes the Annual Report for the Financial Year 2018

Immunovia has today published the annual report for 2018 in Swedish. It is available on Immunovia's website. Mats Grahn, CEO, comments: "We entered...


Mar 04, 2019, 02:16 ET Immunovia Provides an Update on the Optimization Work to Meet the Expected Performance for Commercialization of IMMray™ PanCan-d

Immunovia AB (publ) ("Immunovia") today announced an update on the optimization process to refine the algorithms and eliminate any potential...


Feb 14, 2019, 11:28 ET Immunovia Full Year Report, January-December 2018

Throughout 2018, we continued to build on our mission to develop and validate accurate bloodbased diagnostic tests that can make a real and...


Feb 14, 2019, 10:09 ET Immunovia to Participate in Upcoming Investor Conferences in March

Immunovia AB today announced that Mats Grahn, Chief Executive Officer, will participate and host one-on-one investor meetings at the following...


Feb 12, 2019, 09:06 ET Invitation to Presentation of Immunovia´s Full Year Report 2018 on February 14, 2019

Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 – 6:30 p.m. CET. Immunovia will publish...


Feb 12, 2019, 08:16 ET Immunovia AB Announces Appointment of Senior Director of Investor Relations

(Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director of...


Nov 13, 2018, 08:52 ET Immunovia Invited to Present at Jefferies 2018 London Healthcare Conference

Immunovia (Nasdaq Stockholm: IMMNOV), today announced that the Company has been invited to present at the Jefferies 2018 London Healthcare Conference ...


Nov 13, 2018, 06:21 ET McGill, Yale and Universities of Pennsylvania and Massachusetts Join PanFAM-1, the Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer

Immunovia AB today announced that four additional North American Familial Pancreatic Cancer (FPC) sites are to participate in PanFAM-1, the largest...


Nov 07, 2018, 02:59 ET Immunovia Interim Report January-September 2018

Immunovia's IMMray™ platform for blood-based biomarker signatures offers exciting new opportunities to develop accurate diagnostic tests that can...


Nov 06, 2018, 14:36 ET Immunovia Sponsors Primary Care Educational Symposium at Fenway Park in Honor of World Pancreatic Cancer Day

On November 15, 2018 Immunovia will sponsor a unique educational symposium for primary care clinicians in honor of World Pancreatic Cancer Day. The...


Nov 05, 2018, 11:10 ET Invitation to Presentation of Immunovia´s Interim Report January-September 2018 on November 7, 2018

Immunovia will publish the company's interim report for the period January-September 2018 on Wednesday, November 7, at 08:30 a.m. CET. Immunovia...


Oct 26, 2018, 05:41 ET Immunovia AB (Publ) Nomination Committee Appointed for AGM 2019

The Nomination Committee, which is to be appointed for the period until a new Nomination Committee has been appointed, will have four members, of...


Oct 08, 2018, 08:03 ET Immunovia Announces Strategic Focus Centered on IMMray™ Blood-based Biomarker Signatures for Rheumatoid Arthritis Within Autoimmunity

ncouraged by the promising discovery study results previously reported, Immunovia´s prime focus in autoimmunity testing will be to develop IMMray™...


Oct 04, 2018, 08:18 ET Immunovia PanFAM-1 Clinical Trial now Available on ClinicalTrials.gov, the Largest Clinical Trials Database in the World

Immunovia has developed a blood based biomarker signature for early detection of pancreatic cancer called IMMray™ PanCan-d. To validate IMMray™...


Sep 28, 2018, 07:00 ET Invitation to Conference Call Regarding Immunovia's Autoimmune Diseases Strategy on October 8, 2018

Immunovia announced recently that a new study confirms that IMMray™ blood test successfully addresses one of the major challenges in autoimmune...


Aug 24, 2018, 04:46 ET Immunovia Interim Report, January-June 2018

"On 3 April, trading in Immunovia's shares started on NASDAQ Stockholm's main market, where we are listed in the Mid Cap segment. During the second...


Aug 23, 2018, 03:50 ET Invitation to presentation of Immunovia's Interim Report January-June 2018 and Comments to the Previously Published Autoimmunity Study Results

Immunovia will publish the company's interim report for the period January-June 2018 on Friday, August 24, at 08:30 a.m. CET. Immunovia invites to a...


Aug 22, 2018, 08:36 ET Breakthrough in Autoimmune Testing - IMMrayTM Based Novel Biomarker Signature Identifies Patients With Anti-CCP Negative Rheumatoid Arthritis

Immunovia today announced that a new study confirms that the IMMray™ blood test successfully addresses one of the major challenges in autoimmune...


Aug 15, 2018, 03:35 ET Journal of Clinical Oncology Publishes That IMMray™ PanCan-d Serum Biomarker Test Detects Early Pancreatic Cancer With 96% Accuracy

mmunovia AB announced today that the prestigious Journal of Clinical Oncology (JCO) publishes the results of the major retrospective clinical...


Aug 03, 2018, 11:06 ET Karolinska Institutet Participates in Immunovia's PanFAM-1 Prospective Clinical Study for Early Detection of Pancreatic Cancer Using Blood-based Test

Immunovia AB today announced that the Karolinska Institutet is to participate in PanFAM-1, the largest ever prospective study looking at early...